Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

At a glance: a guide to APMS

GPs have been given further evidence that they can confidently prescribe ?-blockers in heart failure patients with COPD or asthma.

The University of Texas study of 1,067 patients with chronic heart failure, 35.9 per cent of who were on ?-blockers, found that use of the drugs did not increase respiratory events per year in patients with COPD or asthma.

Researchers claimed: 'The proven mortality benefit of

?-blockers after myocardial infarction and congestive heart failure mandates their use in patients with obstructive lung disease wherever possible.'

Dr Rubin Minhas, a GP in Gillingham, Kent, and member of the Primary Care Cardiovascular Society, said the findings were unsurprising.

He said: 'It's justifiable to try cardioselective ?-blockers in patients who don't have a reactive component to their COPD although most clinicians probably wouldn't feel comfortable to attempt it.' Last week Pulse revealed that GPs remain confused about when ?-blockers are contra-indicated in airways disease.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say